Syndax Pharmaceuticals, Inc. (SNDX) Analysts See $-1.02 EPS

April 23, 2018 - By Louis Casey

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Logo

Analysts expect Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to report $-1.02 EPS on May, 14.They anticipate $0.31 EPS change or 43.66 % from last quarter’s $-0.71 EPS. After having $-0.80 EPS previously, Syndax Pharmaceuticals, Inc.’s analysts see 27.50 % EPS growth. The stock decreased 5.44% or $0.6 during the last trading session, reaching $10.43. About 184,622 shares traded. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has risen 7.53% since April 23, 2017 and is uptrending. It has underperformed by 4.02% the S&P500.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company has market cap of $257.60 million. The company's lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It currently has negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.